Angela Dussan
Corneal and Contact Management · Long Island City, NYNPI 1205115474
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations.
Across 110 payments — averaging $51.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$592
- Sight Sciences, Inc.$582
- Coopervision Inc.$576
- Bausch & Lomb Americas Inc.$564
- Tarsus Pharmaceuticals, Inc.$493
- Oyster Point Pharma, Inc.$481
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,647100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 12 | $592 |
| Sight Sciences, Inc. | 11 | $582 |
| Coopervision Inc. | 12 | $576 |
| Bausch & Lomb Americas Inc. | 7 | $564 |
| Tarsus Pharmaceuticals, Inc. | 16 | $493 |
| Oyster Point Pharma, Inc. | 11 | $481 |
| Eyevance Pharmaceuticals LLC | 3 | $436 |
| Sun Pharmaceutical Industries Inc. | 10 | $353 |
| Lumenis BE Inc | 1 | $281 |
| Shire North American Group Inc | 2 | $250 |
| Regeneron Healthcare Solutions, Inc. | 2 | $242 |
| Johnson & Johnson Vision Care, Inc. | 6 | $145 |
| AbbVie(2 entities) | 2 | $145 |
| Harrow Eye, LLC | 5 | $130 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $120 |
| Sanofi | 1 | $56 |
| Dompe US, Inc. | 2 | $50 |
| Kala Pharmaceuticals, Inc. | 2 | $43 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $38 |
| Novartis | 1 | $25 |
| LKC Technologies, Inc. | 1 | $23 |
| Thea Pharma Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$375
- Tobradex ST$299
- optilight$281
- Precision 1$274
- EYLEA$242
- TYRVAYA$235
- LOTEMAX SM$234
- INFUSE$150
- TearCare SmartLid$146
- TEARCARE(TM) (2.2) SYSTEM KIT$146
- Zerviate$137
- DAILIES$128
- TEARCARE SYSTEM$126
- XDEMVY$125
- MIEBO$125
- OMNI(R) SURGICAL SYSTEM (US)$124
- CEQUA$124
- VUITY$123
- ALREX$120
- BEPREVE$120
How this compares
$5,647 in reported general payments places this provider in the 85th percentile of 68 corneal and contact management providers in New York.
See all corneal and contact management providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 67 | $41,831 |
| XiidraLifitegrast | 27 | $18,303 |
| TyrvayaVarenicline Tartrate | 19 | $11,477 |
| MieboPerfluorohexyloctane/Pf | 15 | $10,899 |
| Cyclosporine | 14 | $2,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $145 | $41,83167 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $564 | $29,20242 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $481 | $11,47719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 68 corneal and contact management providers in New York.
Other corneal and contact management in Long Island City
- Michele LaganaHoneoye Falls$248K
- Avani DaveBuffalo$122K
- Kevin RosinNew York$59K
- Jeffrey CooperBrooklyn$52K
- Kevork NiksarliNew York$27K
- Richard MalaraBaldwinsville$8K
- David BraunSyracuse$7K
- Michael RaffBrockport$6K
- Christina ChernyNew York$5K
- Nadine EisenbergNew York$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.